Cost sharing payments to collaboration partners recorded as expenses in research and development expenses in the Condensed Consolidated Statements of Operations and Comprehensive Income (Loss), and cost sharing reimbursements from collaboration partners recorded as an offset to expense in research and development expenses in the Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) are as follows (in thousands):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2026		2025		2026		2025
Takeda Collaboration Agreement:
PTV:PGRN cost sharing (reimbursements)	$	—	$	(1,929)	$	(3,130)	$	(4,864)
ATV:TREM2 cost sharing (reimbursements)	—		—		—		(147)
Total Takeda cost sharing (reimbursements)(1)	—		(1,929)		(3,130)		(5,011)
Biogen Collaboration Agreement: LRRK2 cost sharing payments(2)	732		4,100		6,619		12,980
Net cost sharing payments (reimbursements)	$	732	$	2,171	$	3,489	$	7,969

_________________________________

(1)No cost sharing reimbursement asset or liability was recorded as of September 30, 2026. As of December 31, 2025, $1.6 million of cost sharing reimbursements was recorded as a receivable within prepaid expenses and other current assets on the Condensed Consolidated Balance Sheets.

(2)Cost sharing payments due to Biogen of $0.7 million and $2.8 million were recorded within other accrued expenses and other current liabilities on the Condensed Consolidated Balance Sheets as of September 30, 2026 and December 31, 2025, respectively.